2 news items
Spyre Therapeutics Appoints Accomplished Biopharma Leader Dr. Sandra Milligan to its Board of Directors
SYRE
15 May 24
the expected benefits or opportunities with respect to its pipeline of product candidates such as potential improved dosing regimens over approved
Spyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
SYRE
9 May 24
and safety profile of its product candidates, the potential therapeutic benefits and economic value of its product candidates, the timing and results
- Prev
- 1
- Next